Introduction. Herpes Zoster is a painful cutaneous rash, consisting of vesicles on a erythematosus, with dermatome distribution, caused by reactivating latent infection with the varicella-zosterian virus. The incidence increases with age. It is very rare in children. The disease affects both healthy and immunocompromised adults. About 50% of the over 85 years old may develop the condition. Aim of the study. Appreciation of the basic aspects of etiopathogenesis, evolution and pharmaceutical assistance of Herpes Zoster..Material and methods. The analysis of 40 records of patients with Herpes Zoster from the adult dermatovenerology department of the Dermatology Hospital and Communicable Diseases. Results. Based on the results obtained, it was found that the most common dermatomes involved are those in the chest region with over 50% of the total analyzed patients, namely the affected areas were T5-T8 and T2-T4. Also in 33% of the cases, rashes were met on the dermatomes in the scalp region. 36% of patients accused pronounced pain in the affected area and 19% of them also expressed post-herpetic neuralgia, which is practically the most common complication. All patients (100%), were subjected to vitamin-therapy and antiviral medication therapy, in most cases patients received remedies from anti-bacterial and anti-inflammatory preparations groups -73%, they were also given anti-fungal treatment - 21% and depending on the severe complications and associated diseases, remedies from other groups, such as sedatives - 18%. The most commonly used antivirals are: acyclovir, with a predominance of the incidence of administration - 65% of the cases, followed by Valacyclovir with 20% of the cases. Conclusions. The prophylactic treatment consists of immunization against VVZ. The drug treatment is specific to the type of virus that causes the disease. For Herpes Zoster, oral treatment with antivirals is recommended: Acyclovir (800 mg x 5/day, 7 days), Valacyclovir (1000 mg x 3/day, 7 days), Famciclovir, Brivudin. The beginning of the treatment is recommended within the first 72 hours after the onset of the rash, in order to reduce the duration of the episode and the severity of the lesions, the rate of systemic complications and the risk of postherpetic neuralgia.